Hepatocellular Carcinoma: Clinical Trials

620 trials for Hepatocellular Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

179 unknown, 175 completed, 87 recruiting, 78 terminated. 620 Phase 2, 128 Phase 1, 47 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2620Unknown 179, Completed 175, Recruiting 87, Terminated 78, Withdrawn 40, Active not recruiting 35, Not yet recruiting 21, Suspended 4, Enrolling by invitation 1
Phase 1128Completed 39, Unknown 32, Terminated 23, Recruiting 17, Active not recruiting 7, Withdrawn 7, Not yet recruiting 2, Suspended 1
Phase 347Unknown 22, Terminated 5, Withdrawn 5, Completed 4, Recruiting 4, Active not recruiting 3, Not yet recruiting 2, Suspended 2

Follow Hepatocellular Carcinoma: new trials by email Literature Review of Hepatocellular Carcinoma trials Research Report on Hepatocellular Carcinoma

Trials (filtered) newest first · largest first

All 620 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC
Lenvatinib, Partial transarterial chemoembolization (TACE) - Hepatocellular Carcinoma
Phase 2Not yet recruitingChang Gung Memorial Hospital402026-11-302026-11-03
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
BGB-B2033 - Hepatocellular Cancer, Liver Cancer
Phase 2Not yet recruitingBeOne Medicines1002026-11-302026-11-03
Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) in Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy
BMS-TACE, Pirarubicin, Blank microspheres - Hepatocellular Carcinoma, Liver Neoplasms
Phase 2RecruitingSun Yat-sen University432026-10-202026-11-19
Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy - Hepatocellular Carcinoma
Phase 2RecruitingAnhui Provincial Hospital602026-09-162026-09-21
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
Regorafenib, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization - Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
Phase 2WithdrawnUniversity of Miami2026-08-012026-06-15
Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
NRT6003 Injection - Hepatocellular Carcinoma
Phase 2Not yet recruitingSecond Affiliated Hospital of Guangzhou Medical University202026-06-222026-06-18
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
Lu-PSMA-617 - Liver Cancer, Hepatocellular Carcinoma
Phase 2RecruitingMelissa Lumish102026-06-012026-05-08
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Durvalumab, Zanzalintinib - Hepatocellular Carcinoma, Liver Cancer
Phase 2Not yet recruitingAmit Mahipal162026-05-012026-05-05
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma
Phase 1 / Phase 2Not yet recruitingBinYong Liang1002026-04-302026-04-13
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
MRG006A, Pucotenlimab, Bevacizumab - Hepatocellular Carcinoma
Phase 1 / Phase 2RecruitingLepu Biopharma Co., Ltd.1602026-04-082026-07-28
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Hydroxychloroquine, Lipiodol, Placebo - Hepatocellular Carcinoma
Phase 1 / Phase 2RecruitingVA Office of Research and Development932026-04-012026-11-17
Clinical Trial of TB511 in Advanced Solid Tumors
TB511, Keytruda - NSCLC, Prostate Cancer
Phase 1 / Phase 2Not yet recruitingTwinpig Biolab, Inc.122026-03-012025-11-25
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
sintilimab combined with bevacizumab biosimilar - Hepatocellular Carcinoma, Neoadjuvant Therapy
Phase 2RecruitingSun Yat-sen University372026-01-142026-01-16
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Atezolizumab combined with bevacizumab combined with β- alanine, Atezolizumab combined with bevacizumab - Hepatocellular Carcinoma
Phase 2RecruitingPeking Union Medical College Hospital1582025-12-242026-01-05
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Apatinib, Camrelizumab, TACE - Hepatocellular Carcinoma
Phase 2 / Phase 3Not yet recruitingShanghai Zhongshan Hospital2222025-12-222025-12-30
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma
Phase 2RecruitingMayo Clinic272025-12-182026-09-30
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
PF-08634404, Ipilimumab - Carcinoma, Hepatocellular, Hepatocellular Cancer
Phase 1 / Phase 2RecruitingPfizer1382025-12-012026-10-08
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
Systemic therapy, Radiotherapy - Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Phase 2TerminatedShandong Cancer Hospital and Institute22025-11-302026-11-18
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab, HAIC (GEMOX) - Hepatocellular Carcinoma
Phase 2 / Phase 3RecruitingUNICANCER1962025-11-142026-02-03
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
nivolumab, pembrolizumab - Renal Cell Carcinoma, Non Small Cell Lung Cancer
Phase 2RecruitingDiwakar Davar8802025-11-042026-04-16

Showing 20 of 620. Sign in to see all of them.

Narrower conditions

Carcinoma, Hepatocellular (620)  ·  Liver Neoplasms (82)  ·  Carcinoma, Non-Small-Cell Lung (26)  ·  Colorectal Neoplasms (24)  ·  Neoplasms (24)  ·  Stomach Neoplasms (21)  ·  Carcinoma, Renal Cell (20)  ·  Cholangiocarcinoma (18)  ·  Melanoma (14)  ·  Neoplasm Metastasis (12)  ·  Pancreatic Neoplasms (11)  ·  Squamous Cell Carcinoma of Head and Neck (10)  ·  Carcinoma (9)  ·  Fibrosis (9)  ·  Urinary Bladder Neoplasms (9)

Broader conditions

Digestive System Diseases (618)  ·  Neoplasms by Histologic Type (618)  ·  Neoplasms by Site (618)  ·  Neoplasms, Glandular and Epithelial (618)  ·  Adenocarcinoma (617)  ·  Digestive System Neoplasms (614)  ·  Liver Diseases (612)  ·  Carcinoma (611)  ·  Neoplasms (596)  ·  Liver Neoplasms (538)  ·  Gastrointestinal Diseases (43)  ·  Pathological Conditions, Signs and Symptoms (39)  ·  Gastrointestinal Neoplasms (38)  ·  Pathologic Processes (37)  ·  Lung Diseases (31)

Interventions

Sorafenib (63)  ·  Bevacizumab (53)  ·  lenvatinib (52)  ·  Nivolumab (35)  ·  sintilimab (30)  ·  durvalumab (29)  ·  atezolizumab (26)  ·  pembrolizumab (26)  ·  apatinib (23)  ·  Fluorouracil (19)  ·  Oxaliplatin (19)  ·  camrelizumab (18)  ·  tremelimumab (17)  ·  Folfox protocol (16)  ·  Radiosurgery (16)

Sponsors

Sun Yat-sen University (43)  ·  Fudan University (13)  ·  National Cancer Institute (NCI) (11)  ·  Shanghai Zhongshan Hospital (11)  ·  Tianjin Medical University Cancer Institute and Hospital (11)  ·  Guangxi Medical University (10)  ·  Seoul National University Hospital (9)  ·  Zhejiang University (9)  ·  Eastern Hepatobiliary Surgery Hospital (8)  ·  Asan Medical Center (7)  ·  National Taiwan University Hospital (7)  ·  University Health Network, Toronto (7)  ·  Akeso (6)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6)  ·  Peking Union Medical College Hospital (6)

Countries

China (236)  ·  United States (165)  ·  South Korea (62)  ·  Taiwan (56)  ·  France (36)  ·  Spain (30)  ·  Germany (26)  ·  Hong Kong (26)  ·  Italy (24)  ·  Canada (21)  ·  Japan (21)  ·  Singapore (19)  ·  United Kingdom (16)  ·  Belgium (13)  ·  Israel (7)

Top investigators

Ming Shi, MD (8)  ·  Tim F Greten, M.D. (6)  ·  David Hsieh, MD (4)  ·  Feng Shen, M.D. (3)  ·  Gao-Jun Teng, MD (3)  ·  Jin Woo Choi, MD, PhD (3)  ·  Lequn Li, PhD (3)  ·  Mi-Sook Kim, MD, PhD (3)  ·  Mian Xi, MD (3)  ·  Peng Wang, MD (3)  ·  Xiaodong Wang, MD (3)

Results publications

PMID 36852452, PMID 12049862, PMID 19192962, PMID 12540794, PMID 28434648, PMID 29366520, PMID 29543938, PMID 29875066, PMID 31401903, PMID 33856599, PMID 34143971, PMID 36529152, PMID 37981041, PMID 39437804, PMID 11419162, PMID 11668491, PMID 11981766, PMID 12091661, PMID 14667750, PMID 15508079, PMID 15508084, PMID 15623621, PMID 15831268, PMID 15868910, PMID 16495695, PMID 16527888, PMID 16951235, PMID 17543307, PMID 18565579, PMID 18834631, PMID 18981929, PMID 19097774, PMID 20149262, PMID 20332205, PMID 20390419, PMID 20516446, PMID 20717115, PMID 20724077, PMID 20839057, PMID 21058409, PMID 21123824, PMID 21264826, PMID 21277098, PMID 21321535, PMID 21338641, PMID 21487286, PMID 21935635, PMID 22033636, PMID 22075702, PMID 22210086

NIH funding

2018 (3), 2019 (3), P30CA060553 (3), 2015 (2), 2017 (2), 2023 (2), P30CA012197 (2), 2005 (1), 2008 (1), 2014 (1), 2016 (1), 2025 (1), I01CX002542 (1), N01CN00035 (1), N01CN00042 (1)